At the time of insulin initiation, physicians often discontinue oral therapies in patients with T2D. A recent randomized clinical trial demonstrated continuing sitagliptin, a DPP-4i, results in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycemia. An online U.S. physician survey (n=400) is being conducted to understand reasons for discontinuation of DPP-4i therapy. Preliminary analysis is based on completed surveys (n=180; 41 endocrinologists, 74 family practice, 63 internal medicine, 2 diabetologists) from physicians treating a monthly average of 137 patients. Table lists key physician characteristics and their responses for continuing/discontinuing DPP-4i on initiation of insulin. The top responses for continuing DPP-4i include meeting treatment goals, using a lower dose of insulin, good tolerability, reducing weight gain and hypoglycemia. The top responses for discontinuing include adverse events/tolerability, cost, treatment goals not being met, patient preference, and prior authorization requirements. In this ongoing study, further data is being collected on the remaining physician sample and a medical chart review will be conducted on a sub-sample of patients treated by these physicians to explore patient characteristics associated with DPP-4i discontinuation.


G. Fernandes: None. D.H. Jaffe: Consultant; Self; Merck & Co., Inc. G. DiBonaventura Beyer: None. J.E. Matos: None. K. Iglay: Employee; Self; Merck & Co., Inc. Stock/Shareholder; Self; Merck & Co., Inc. I. Gantz: Employee; Self; Merck & Co., Inc. S. Rajpathak: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at